Washington University School of Medicine

Digital Commons@Becker
Open Access Publications
2015

Multiplatform molecular profiling identifies potentially targetable
biomarkers in malignant phyllodes tumors of the breast
Zoran Gatalica
Caris Life Sciences

Semir Vranic
University Clinical Center Sarajevo

Anatole Ghazalpour
Caris Life Sciences

Joanne Xiu
Caris Life Sciences

Idris Tolgay Ocal
Mayo Clinic

See next page for additional authors

Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs

Recommended Citation
Gatalica, Zoran; Vranic, Semir; Ghazalpour, Anatole; Xiu, Joanne; Ocal, Idris Tolgay; McGill, John; Bender,
Ryan P.; and Discianno, Erin, ,"Multiplatform molecular profiling identifies potentially targetable biomarkers
in malignant phyllodes tumors of the breast." Oncotarget. ,. 1-10. (2015).
https://digitalcommons.wustl.edu/open_access_pubs/4414

This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been
accepted for inclusion in Open Access Publications by an authorized administrator of Digital Commons@Becker.
For more information, please contact vanam@wustl.edu.

Authors
Zoran Gatalica, Semir Vranic, Anatole Ghazalpour, Joanne Xiu, Idris Tolgay Ocal, John McGill, Ryan P.
Bender, and Erin Discianno

This open access publication is available at Digital Commons@Becker: https://digitalcommons.wustl.edu/
open_access_pubs/4414

Oncotarget, Advance Publications 2015

www.impactjournals.com/oncotarget/

Multiplatform molecular profiling identifies potentially targetable
biomarkers in malignant phyllodes tumors of the breast
Zoran Gatalica1, Semir Vranic2, Anatole Ghazalpour1, Joanne Xiu1, Idris Tolgay Ocal3,
John McGill4, Ryan P. Bender1, Erin Discianno1, Aaron Schlum1, Souzan Sanati5,
Juan Palazzo6, Sandeep Reddy1, Barbara Pockaj3
1

Caris Life Sciences, Phoenix, AZ, United States of America

2

Department of Pathology, University Clinical Center Sarajevo, Sarajevo, Bosnia and Herzegovina

3

Mayo Clinic, Scottsdale, AZ, United States of America

4

Miraca Life Sciences, Phoenix, AZ, United States of America

5

 ivision of Anatomic and Molecular Pathology, Washington University School of Medicine, Saint Louis, MO, United States of
D
America

6

Department of Pathology, Anatomy, and Cell Biology, Jefferson Medical College, Philadelphia, PA, United States of America

Correspondence to: Zoran Gatalica, e-mail: zgatalica@carisls.com
Keywords: breast, fibroepithelial tumors, malignant phyllodes tumor, biomarkers, molecular profiling
Received: November 04, 2015

Accepted: November 17, 2015

Published: November 28, 2015

ABSTRACT
Malignant phyllodes tumor is a rare breast malignancy with sarcomatous
overgrowth and with limited effective treatment options for recurrent and metastatic
cases. Recent clinical trials indicated a potential for anti-angiogenic, anti-EGFR and
immunotherapeutic approaches for patients with sarcomas, which led us to investigate
these and other targetable pathways in malignant phyllodes tumor of the breast.
Thirty-six malignant phyllodes tumors (including 8 metastatic tumors with two cases
having matched primary and metastatic tumors) were profiled using gene sequencing,
gene copy number analysis, whole genome expression, and protein expression.
Whole genome expression analysis demonstrated consistent over-expression of
genes involved in angiogenesis including VEGFA, Angiopoietin-2, VCAM1, PDGFRA,
and PTTG1. EGFR protein overexpression was observed in 26/27 (96%) of cases
with amplification of the EGFR gene in 8/24 (33%) cases. Two EGFR mutations
were identified including EGFRvIII and a presumed pathogenic V774M mutation,
respectively. The most common pathogenic mutations included TP53 (50%) and
PIK3CA (15%). Cases with matched primary and metastatic tumors harbored identical
mutations in both sites (PIK3CA/KRAS and RB1 gene mutations, respectively). Tumor
expression of PD-L1 immunoregulatory protein was observed in 3/22 (14%) of cases.
Overexpression of molecular biomarkers of increased angiogenesis, EGFR and immune
checkpoints provides novel targeted therapy options in malignant phyllodes tumors
of the breast.

tumors may also pose a potential therapeutic challenge as
no effective targeted therapy has been reported yet [1, 2].
Previous studies of the molecular genetics of PT
showed the importance of the TP53 gene and p53 protein
in progression from benign to malignant phyllodes tumors
[3–6]. A gene expression study conducted by Vidal et al.
[7] revealed activation of gene clusters related to hypoxia
and angiogenesis in malignant phyllodes cases. Expression
of various angiogenic factors including CD34, CD105,
vascular endothelial growth factor (VEGF) and hypoxia-

INTRODUCTION
Phyllodes tumors (PT) of the breast are rare,
biphasic (fibro-epithelial) neoplasms, constituting ≤ 1%
of all breast cancers [1], and are histologically classified
as benign, borderline or malignant. The malignant variant
is characterized by an overgrowth of the malignant stromal
(sarcomatous) component and constitutes ~20% of all
phyllodes tumors. There is a significant potential (~22%)
for both local recurrence and distant metastasis [1]. These
www.impactjournals.com/oncotarget
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Unequivocal EGFRvIII mutant case also harbored EGFR
gene amplification. Activating EGFR gene mutation was
observed in one primary phyllodes tumor (presumed
pathogenic V774 mutation). This case also overexpressed
EGFR protein without EGFR gene amplification or any
other potentially targetable mutations.

inducible factor-alpha has also been reported in malignant
phyllodes tumors [8–11]. Tse et al. [12] also found the
tumor angiogenesis (measured by microvessel density)
as an independent predictor of malignancy in phyllodes
tumors. Recent gene sequencing studies revealed the
presence of variety of mutations in malignant phyllodes
tumors of which MED12 [Mediator Complex Subunit 12]
mutation appears to be the most consistent and shared by
both malignant and benign fibroepithelial tumors [13–15].
However, truly actionable (targetable by specific drugs)
genetic alterations in PT appear to be rare. Majority of the
previous studies showed EGFR protein overexpression and
EGFR gene amplification in PT [13, 16–18]; However, Tse
et al. [19] reported a low EGFR amplification rate (8%)
in EGFR protein positive phyllodes tumors. No targetable
EGFR activating mutations have been reported thus far.
Recently, cancer immunoediting involving immune
check point proteins programmed cell death-1 (PD-1/
CD279) expressed on tumor infiltrating T-lymphocytes
and its ligand (PD-L1/CD274) expressed on tumor cells
have come into the clinical focus due the remarkable
therapeutic benefits caused by their specific inhibitors in
patients with advanced melanoma, renal cell carcinoma
and non-small cell lung carcinoma [20–21]. PD-1/PDL1 expression was also reported in soft tissue sarcomas,
which indicated a potential for targeting this pathway in a
variety of cancers [20, 22–26].
In the present study, we comprehensively profiled
a series of malignant phyllodes tumors of the breast in
an attempt to identify potentially targetable pathways/
biomarkers.

Immune check-point proteins (PD-1 and PD-L1)
PD-1 and its ligand PD-L1 were evaluated in
22 phyllodes cases. Eight cases (36%) exhibited scattered,
below threshold PD-L1 positivity on neoplastic cells while
3 cases including one metastatic phyllodes tumor showed
positivity above the 5% threshold. In some cases PD-L1
expression was also detected on mono-nuclear cells within
and surrounding the tumor (Figure 2). PD-1 positive TILs
were completely absent in 12 cases, while in other cases
varied in density from 1/10 hpf to > 100/10 hpf.
Mutational profile
NGS and/or Sanger sequencing assays were
successful in 27 cases (Table 1). Apart from the above
described EGFR mutations, several other genes were
mutated including: TP53 and, PIK3CA (affecting 50%
and 15% of cases respectively), and BRCA1, BRCA2,
RET, CDH1, MLH1, ATM, KRAS, and RB1 (all affecting
single phyllodes cases; Table 1). Of note, two cases with
matching primary and metastatic (lung) samples harbored
identical mutations in both sites: case#1 affecting a
56-year-old female had PIK3CA (H1047L) and KRAS
(G12D) while case#2 (43-year-old female) harbored RB1
(P347fs) gene mutation. Of note, no mutations in KDR
(VEGFR2) were detected (n = 27).

RESULTS

Whole genome expression profiling

Patients

Differential expression analysis of the mRNA as
measured by the Illumina array platform was carried out
by comparing the normalized expression of the transcripts
to the expression of the genes in the normal breast
tissue. At the two fold cutoff, 247 probes representing
243 genes were found to be up regulated and 443 probes
representing 422 genes were found to be down regulated
(Figure 3, Supplementary Table 1). List of upregulated
genes includes the 57 probes (57 genes) and 19 probes
(18 genes) that were upregulated by 5 fold. The list of
significantly enriched Gene Ontology (GO) terms included
terms associated with GTPase activity, cytokine binding,
and several cell division terms.
We found that 6 angiogenic markers (VEGFA,
Angiopoietin-2, VCAM1, PDGFRA, PTTG1, and
CYP3A5) were differentially expressed by at least 2 fold in
phyllodes patients when compared with control (Figure 4,
Supplementary Table 1). Moreover, our list significantly
overlapped with the “angiome” list as published by
Rivera et al. [31] (17 common genes, hypergeometric test
p-value = 0.005).

The study included 36 malignant (high grade)
phyllodes tumors of which 24 were primary, 8 metastatic
and 4 recurrent malignant phyllodes tumors of the
breast (Table 1). Two metastatic phyllodes cases (lung
metastasis) had their primary site samples available for
molecular testing. All patients were females with the mean
age of 50.8 years (range, 17–76 years).

Tumor characteristics
EGFR status
EGFR protein overexpression (H-score ≥ 20) was
observed in 26 of 27 tested cases (96%) while amplification
of the EGFR gene was observed in 8 of 24 tested cases
(33%); all EGFR amplified cases strongly overexpressed
EGFR protein (H-score > 200) (Figure 1A–1D). EGFRvIII
mutant variant was unequivocally detected in one out of
29 tested cases (~3%); an additional case exhibited a
borderline MLPA score (0.8). Both cases were primary
phyllodes tumors overexpressing EGFR protein by IHC.
www.impactjournals.com/oncotarget
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Table 1: Results of multiplatform molecular profiling of 36 malignant phyllodes cases
Case (site)

PD-L1 protein
(IHC)

EGFR protein
(IHC)

EGFR (ISH)

EGFR
(mutations)

NGS and Sanger (other
mutations)

Case#1 (P)

Negative

Positive

Negative

Wild type

TP53 (G245S)
PIK3CA (H1047R)
PIK3CA (VUS G106_
R108del)

Case#2 (P)

n/a

Positive

Negative

Wild type

None

Case#3 (P)

Negative

Positive

Negative

Wild type

PIK3CA (H1047R)
PIK3CA (E545K)

Case#4 (P)

Negative

Positive

Negative

Wild type

None

Case#5 (P)

Negative

Positive

Negative

Wild type

TP53 (R248Q)

Case#6 (P)

Negative

Positive

Negative

Wild type

RET (VUS S653T)

Case#7 (P)

Negative

Positive

Negative

EGFR (V774M) None

Case#8 (P)

Negative

Positive

Negative

Wild type

PIK3CA (H1047L)

Case#9 (P)

Negative

Positive

Amplified

Wild type

n/a

Case#10 (P)

Positive

Positive

Negative

Wild type

BRCA1 (M17751)
BRCA2 (A371T, VUS)

Case#11 (P)

Negative

Positive

Amplified

Wild type

n/a

Case#12 (R)

Negative

Positive

n/a

Wild type

n/a

Case#13 (P)

Negative

Positive

n/a

Wild type

n/a

Case#14 (P)

Positive

Negative

Negative

Wild type

n/a

Case#15 (P)

Positive

Positive

Amplified

Wild type

TP53 (R248W)
CDH1 (Q422K VUS)

Case#16
P
M

Negative
Positive

Positive
Positive

Negative
Negative

Wild type
Wild type

PIK3CA (H1047L), KRAS
(G12D)
PIK3CA (H1047L), KRAS
(G12D)

Case#17
P
M

Negative
Positive

Positive
Positive

Negative
Negative

Wild type
Wild type

RB1 (P347fs)
RB1 (P347fs)

Case#18 (R)*

n/a

n/a

n/a

n/a

n/a

Case#19 (M)*

n/a

n/a

Amplified

Wild type

n/a

Case#20 (P)*

n/a

Positive

n/a

n/a

TP53 (T140fs) (Y234C)

Case#21 (P)*

n/a

n/a

negative

Wild type

None

Case#22 (M)*

n/a

n/a

Amplified

Wild type

TP53 (R282W)

Case#23 (R)*

n/a

Positive

negative

Wild type

TP53 (G245S)

Case#24 (P)*

n/a

Positive

Amplified

EGFRvIII

n/a

Case#25 (P)*

n/a

Positive

Amplified

Wild type

TP53 (D281V)

Case#26 (M)*

n/a

Positive

Negative

Wild type

TP53 (R175H)

Case#27 (M)

n/a

Positive

Negative

Wild type

TP53 (V157F)

Case#28 (P)

n/a

Positive

n/a

Wild type

None
(Continued )
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Case (site)

PD-L1 protein
(IHC)

EGFR protein
(IHC)

EGFR (ISH)

EGFR
(mutations)

NGS and Sanger (other
mutations)

Case#29 (P)

n/a

Positive

n/a

Wild type

None

Case#30 (R)

n/a

n/a

n/a

n/a

None

Case#31 (P)

n/a

Positive

n/a

Wild type

TP53 (S99fs)

Case#32 (M)

n/a

n/a

Negative

Wild type

TP53 (R175H)

Case#33 (P)

Positive

n/a

n/a

Wild type

MLH1

Case#34 (P)

Positive

Positive

n/a

Wild type

TP53 (L194R)
ATM (T616I)

Case#35 (P)

Positive

Positive

Amplified

Wild type

TP53 (c.560–23_561del)
TP53 (R273H)

Case#36 (M)

Negative

Positive

n/a

Wild type

n/a

Gene expression profiling; IHC – immunohistochemistry; ISH – in situ hybridization; NGS – next-generation sequencing
P – Primary; R – recurrent; M – metastatic
n/a – not available
VUS – variant of unknown significance
*

Figure 1A-D: Primary malignant phyllodes tumor of the breast (A-B H&E stain, 10–20x magnification) with a strong
membranous EGFR protein overexpression (C – IHC stain) accompanied by EGFR gene amplification (D – CISH).
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Figure 2: A case of metastatic phyllodes tumor to the lung with peripheral PD-L1 expression adjacent to the
inflammatory cells and normal lung parenchyma; of note this case harbored RB1 gene mutation in both primary and
metastatic tumor.

Figure 3: Gene expression signature of six phyllodes cases along with the normal breast tissue. In the heatmap, rows

represent genes and columns represent samples. “Upregulated” (depicted in red) is defined as a transcript with transcript level that is > 2
fold relative to normal breast control and down regulated (depicted in blue) is defined as a transcript with transcript level that is < 2 fold
relative to control. The expression of the normal breast is shown in the far left column.
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DISCUSSION

recently reported on a recurrent mammary angiosarcoma
that was successfully treated with anti-angiogenic drug
sunitinib, identified as a potentially beneficial therapy
option using the whole genome array analysis [34].
In addition, anti-angiogenic targeted therapies (e.g.
tyrosine kinase inhibitors, monoclonal antibodies)
are promising therapeutics for the treatment of a wide
spectrum of soft tissue tumors [37]. We also found
overexpression of EGFR protein (with or without EGFR
gene amplification or mutations), which could lead to the
use of dual VEGFR/EGFR inhibitors (e.g. Vandatenib)
or a combination of anti-VEGFR (e.g. bevacizumab) and
anti-EGFR (e.g. erlotinib/gefitinib/cetuximab) therapies
[38, 39]. Overexpression of PDGFRA would suggest
the potential study of pazopanib, a multikinase inhibitor,
with c-KIT, FGFR, PDGFR and VEGFR being amongst
the inhibited enzymes. Of note, we report here for the
first time that EGFRvIII (a mutant form of EGFR with
deletion of exons 2–7 of the gene) may play a role in a
small subset of malignant phyllodes tumors, adding this

Malignant phyllodes tumor of the breast is a rare
malignancy (<1%) with a substantial potential for both
local relapse and distant metastasis (~20%) [1]. Apart
from surgery, no optimal treatment modalities with impact
on overall survival are available at present [32]. Several
recent studies indicated that molecular profiling of such
“orphan tumors” may identify actionable targets with a
successful outcome, even in metastatic setting [13, 22,
33–36].
The present study using comprehensive,
multiplatform molecular approach revealed several
potentially targetable pathways/biomarkers in these
neoplasms. We found upregulation of several
angiogenesis-related
genes
including
VEGFA,
Angiopoietin-2, VCAM1, PDGFRA, and PTTG1 [16–19].
These findings may be clinically relevant as the
upregulation of proangiogenic genes may predict response
to the targeted therapy (e.g. angiogenesis inhibitors). We

Figure 4: Bar plots for 6 angiogenesis markers found to be differentially regulated in Phyllodes cases when compared
to normal breast tissue. The height represents the ratio of expression for the gene in the phyllodes case over the expression in the
normal breast. For CYP3A5, three phyllodes cases had no detectable expression of the transcript and the values are depicted as 0 ratio.
Normal breast expression ratio is set to ‘1’ for all 6 biomarkers and is depicted as the ‘black’ bar for all 6 genes.

www.impactjournals.com/oncotarget
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Immunohistochemistry (IHC)

cancer to the growing list of malignancies with this type of
mutation [40], and potentially eligible for tumor directed
immunotherapy.
The selective mutational profiling (TSACP) of
malignant phyllodes tumors revealed that TP53 and
PIK3CA gene mutations are common. These results are in
line with previous data (COSMIC database, accessed on
July 21, 2015; [41]). In contrast to the study of Tsang et
al. [2] who also sequenced two matched phyllodes cases
without recurrent mutations (SMAD4, IDH1, PIK3CA,
RET, TP53), we found identical mutational profile in both
primary and metastatic phyllodes cases (PIK3CA/KRAS
and RB1 gene mutations, respectively). PIK3CA and
RB1 alterations have been already described in phyllodes
tumors [2, 13, 42] while Tsang et al. [2] found HRAS and
Jardim et al. [33] NRAS in a borderline, and metastatic
phyllodes tumors, respectively. The frequency of PIK3CA
gene mutations in our study (15%) is the highest in
comparison with the previous data [2] and this finding
may imply a potential therapeutic benefit of the treatment
with mTOR inhibitors.
Recently reported expression of the two immune
check point targetable proteins PD-1 and PD-L1
in a variety of solid tumors including some sarcomas
[20–26], led us to investigate them in this cohort of PT.
Here we found that overexpression of PD-L1 characterizes
a small subset of malignant phyllodes tumors including
some metastatic cases, which may lead to the targeted
immunotherapy for these patients. Numerous studies have
reported remarkable benefits from PD-1/PD-L1 blockade
in patients with other malignancies over-expressing PD-L1
(e.g. renal cell carcinoma, NSCLC, malignant melanoma,
[21, 43–44]).
Limitations of our study are related to its
retrospective design and the small number of cases tested
by the Illumina microarray assay. Also, further prospective
studies should confirm the clinical relevance of profilingidentified biomarkers.
In conclusion, this study provides additional support
for comprehensive profiling in PT, which can identify
several potentially targetable pathways including EGFR,
angiogenesis, and immunotherapy for patients with locally
advanced or metastatic tumors.

Expression of EGFR, PD-1 and PD-L1 was
evaluated immunohistochemically using commercially
available antibodies and detection kits [EGFR
(Invitrogen); PD-1, (NAT1 antibody, Cell Marque); antiPD-L1 (SP142, Spring Bioscience)]. The extent of EGFR
expression was evaluated using H-score (intensity of
staining graded on a subjective scale of 0–3 and percentage
of cells with given intensity were multiplied and added
up to provide an H-score, which ranged from 0–300).
Tumor infiltrating lymphocytes (TIL), which expressed
PD-1 on their plasma membrane, were evaluated and their
density (number of PD-1+ TILs per high power field) was
recorded. Membranous expression of PD-L1 in more than
5% of tumor cells was considered positive [20, 22–23, 27].
All IHC assays included positive and negative controls to
support the validity of results.

EGFR gene alterations
Copy number changes: In-situ
(fluorescent and chromogenic ISH)

FISH [EGFR/CEP7 probe] (Abbott Molecular/Vysis)
and CISH (dual EGFR DNP/CEP 7 DIG probes, Ventana,
Tucson, AZ) assays were used for evaluation of the EGFR
gene status. EGFR gene was considered amplified if
EGFR/CEP7 ratio > 2, or > 15 EGFR gene copies per cell
were observed in > 10% of analyzed cells [28].

EGFRvIII mutation: fragment analysis (FA)
sequencing and multiplex ligation-dependent
probe amplification (MLPA)
Mutation analysis for EGFRvIII was performed on
RNA extracted from FFPE tissue in 18 cases. Two sets
of FAM linked primers were used to PCR amplify both
the wild type and mutant EGFR alleles and PCR products
were visualized using an ABI 3500xl. Signal generated
from the wild type allele was used as an amplification
control and samples were considered positive if EGFRvIII
was detected at a level that is 5x typical background
observed. Samples with EGFRvIII signals between 1–5 x
standard background were considered indeterminate and <
1x standard background was considered a negative result.
This assay requires samples to have at least 50% tumor
nuclei [29].
Eleven PTs were evaluated for EGFRvIII status
using a multiplex ligation-dependent probe amplification
(MLPA) assay (SALSA MLPA KIT P315-A1 EGFR,
MRC-Holland
kit,
MRC-Holland,
Amsterdam,
Netherlands). Values between 0.8 - 1.5 were considered
normal, while values < 0.8 as a loss, > 1.5 as a gain and
values > 2 as an amplification.

MATERIALS AND METHODS
Tissue samples
Thirty-six formalin-fixed paraffin-embedded (FFPE)
samples of malignant phyllodes tumors were profiled at
Caris Life Sciences, Phoenix, AZ (Molecular Intelligence
Service™). All samples were previously diagnosed by
referring pathologists and histologic diagnosis was
confirmed centrally by a board certified pathologist.

www.impactjournals.com/oncotarget
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